Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Germline Testing for Predisposition to Myeloid Malignancies

NCT: NCT07112287 · RECRUITING

NCT IDNCT07112287
StatusRECRUITING
Start Date2025-11-10
Completion2033-04-01

Brief Summary

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Frequently Asked Questions

What is Germline Testing for Predisposition to Myeloid Malignancies?

Germline Testing for Predisposition to Myeloid Malignancies is a clinical trial registered under NCT07112287. Current status: RECRUITING.

What is the status of NCT07112287?

The current status of NCT07112287 (Germline Testing for Predisposition to Myeloid Malignancies) is: RECRUITING.

When did Germline Testing for Predisposition to Myeloid Malignancies start?

Germline Testing for Predisposition to Myeloid Malignancies started on 2025-11-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑